NASDAQ:VIGL Vigil Neuroscience (VIGL) Stock Price, News & Analysis $3.31 +0.04 (+1.22%) (As of 09/27/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Vigil Neuroscience alerts: Email Address About Vigil Neuroscience Stock (NASDAQ:VIGL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vigil Neuroscience alerts:Sign Up Key Stats Today's Range$3.28▼$3.3450-Day Range$2.92▼$4.6552-Week Range$2.47▼$9.24Volume57,489 shsAverage Volume259,608 shsMarket Capitalization$131.24 millionP/E RatioN/ADividend YieldN/APrice Target$16.60Consensus RatingModerate Buy Company OverviewVigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.Read More… WARNING: “Buffett Indicator” flashing for first time in 50 years (Ad)The stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future.Take these 4 steps today to protect your retirement NOW Vigil Neuroscience Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks78th Percentile Overall ScoreVIGL MarketRank™: Vigil Neuroscience scored higher than 78% of companies evaluated by MarketBeat, and ranked 264th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingVigil Neuroscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageVigil Neuroscience has only been the subject of 3 research reports in the past 90 days.Read more about Vigil Neuroscience's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vigil Neuroscience are expected to grow in the coming year, from ($2.15) to ($2.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vigil Neuroscience is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vigil Neuroscience is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVigil Neuroscience has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Vigil Neuroscience's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.71% of the float of Vigil Neuroscience has been sold short.Short Interest Ratio / Days to CoverVigil Neuroscience has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vigil Neuroscience has recently decreased by 20.30%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVigil Neuroscience does not currently pay a dividend.Dividend GrowthVigil Neuroscience does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.71% of the float of Vigil Neuroscience has been sold short.Short Interest Ratio / Days to CoverVigil Neuroscience has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vigil Neuroscience has recently decreased by 20.30%, indicating that investor sentiment is improving significantly. News and Social Media3.4 / 5News Sentiment1.14 News SentimentVigil Neuroscience has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Vigil Neuroscience this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Vigil Neuroscience to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vigil Neuroscience insiders have not sold or bought any company stock.Percentage Held by Insiders33.03% of the stock of Vigil Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.64% of the stock of Vigil Neuroscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vigil Neuroscience's insider trading history. Receive VIGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vigil Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Email Address VIGL Stock News HeadlinesVigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Significant Drop in Short InterestSeptember 28 at 7:48 AM | americanbankingnews.comFDA lifts partial clinical hold on Vigil Neuroscience’s Phase I VG-3927 trialSeptember 20, 2024 | msn.comWARNING: “Buffett Indicator” flashing for first time in 50 yearsThe stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future.September 29, 2024 | Behind the Markets (Ad)Buy Rating Affirmed for Vigil Neuroscience Inc. as FDA Lifts Clinical Hold and Phase 1 Trials Show PromiseSeptember 18, 2024 | markets.businessinsider.comVigil Neuroscience Says FDA Lifts Partial Hold Alzheimer's-Treatment TrialSeptember 17, 2024 | marketwatch.comVigil says FDA removed partial hold on Alzheimer’s candidateSeptember 17, 2024 | msn.comVigil Neuroscience, Inc.: Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927September 17, 2024 | finanznachrichten.deVigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927September 17, 2024 | globenewswire.comSee More Headlines VIGL Stock Analysis - Frequently Asked Questions How have VIGL shares performed this year? Vigil Neuroscience's stock was trading at $3.38 at the start of the year. Since then, VIGL shares have decreased by 2.1% and is now trading at $3.31. View the best growth stocks for 2024 here. How were Vigil Neuroscience's earnings last quarter? Vigil Neuroscience, Inc. (NASDAQ:VIGL) announced its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.02. When did Vigil Neuroscience IPO? Vigil Neuroscience (VIGL) raised $112 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 7,000,000 shares at $15.00-$17.00 per share. How do I buy shares of Vigil Neuroscience? Shares of VIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/13/2024Today9/29/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VIGL CUSIPN/A CIK1827087 Webvigilneuro.com Phone857-254-4445FaxN/AEmployees69Year FoundedN/APrice Target and Rating Average Stock Price Target$16.60 High Stock Price Target$23.00 Low Stock Price Target$4.00 Potential Upside/Downside+401.5%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-76.02% Return on Assets-62.85% Debt Debt-to-Equity RatioN/A Current Ratio8.39 Quick Ratio8.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book1.02Miscellaneous Outstanding Shares39,650,000Free Float25,170,000Market Cap$131.24 million OptionableNot Optionable Beta1.96 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:VIGL) was last updated on 9/29/2024 by MarketBeat.com Staff From Our PartnersWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredCongress passes legislation in favor of Musk-backed technology Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredThe $15 "Insider Secret" That Could Save Your RetirementWhat if I told you there's a $15 stock that a billionaire insider just poured $47 MILLION into? That's righ...Behind the Markets | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vigil Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vigil Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.